DE60232413D1 - Ltb4 als adjuvans für impfstoffe - Google Patents

Ltb4 als adjuvans für impfstoffe

Info

Publication number
DE60232413D1
DE60232413D1 DE60232413T DE60232413T DE60232413D1 DE 60232413 D1 DE60232413 D1 DE 60232413D1 DE 60232413 T DE60232413 T DE 60232413T DE 60232413 T DE60232413 T DE 60232413T DE 60232413 D1 DE60232413 D1 DE 60232413D1
Authority
DE
Germany
Prior art keywords
ltb4
impfstoffe
adjuvans
für
als
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60232413T
Other languages
English (en)
Inventor
Louis Flamand
Jean Gosselin
Pierre Borgeat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTB4 Sweden AB
Original Assignee
LTB4 Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTB4 Sweden AB filed Critical LTB4 Sweden AB
Application granted granted Critical
Publication of DE60232413D1 publication Critical patent/DE60232413D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Vending Machines For Individual Products (AREA)
  • Amplifiers (AREA)
  • Refinement Of Pig-Iron, Manufacture Of Cast Iron, And Steel Manufacture Other Than In Revolving Furnaces (AREA)
DE60232413T 2001-07-05 2002-06-26 Ltb4 als adjuvans für impfstoffe Expired - Lifetime DE60232413D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30270501P 2001-07-05 2001-07-05
PCT/CA2002/000955 WO2003004054A1 (en) 2001-07-05 2002-06-26 Ltb4 as vaccine aduvant

Publications (1)

Publication Number Publication Date
DE60232413D1 true DE60232413D1 (en) 2009-07-02

Family

ID=23168877

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60232413T Expired - Lifetime DE60232413D1 (en) 2001-07-05 2002-06-26 Ltb4 als adjuvans für impfstoffe

Country Status (8)

Country Link
US (1) US7914800B2 (de)
EP (1) EP1401492B1 (de)
AT (1) ATE431745T1 (de)
CA (1) CA2452008C (de)
DE (1) DE60232413D1 (de)
DK (1) DK1401492T3 (de)
ES (1) ES2329118T3 (de)
WO (1) WO2003004054A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473708B2 (en) 1996-02-15 2009-01-06 Jean Gosselin Agents with leukotriene B4-like antiviral (enveloped RNA) activities
US20050239889A1 (en) * 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
US8664271B2 (en) * 2004-09-20 2014-03-04 Ltb4 Sweden Ab Stabilized leukotriene B4 (LTB4) agent pharmaceutical formulation
WO2012000082A1 (en) * 2010-06-29 2012-01-05 UNIVERSITé LAVAL Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-l-like receptor ligand or a nod-like receptor ligand to enhance the innate immune response

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method

Also Published As

Publication number Publication date
CA2452008A1 (en) 2003-01-16
DK1401492T3 (da) 2009-09-14
ATE431745T1 (de) 2009-06-15
EP1401492A1 (de) 2004-03-31
WO2003004054A1 (en) 2003-01-16
US20040208882A1 (en) 2004-10-21
ES2329118T3 (es) 2009-11-23
EP1401492B1 (de) 2009-05-20
US7914800B2 (en) 2011-03-29
CA2452008C (en) 2012-03-06

Similar Documents

Publication Publication Date Title
EP1504112A4 (de) Entwicklung einer vakzine zur prävention von infektionen mit dem filovirus bei primaten
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
NL300458I2 (de)
HK1044484B (zh) 含皂草苷和免疫刺激寡核苷酸的佐劑組合物
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
WO2002026757A3 (en) Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
GB2386072A (en) Novel vaccine
DK0973544T3 (da) Immuntolerant prothrombinkomplekspræparat
WO2003041735A3 (en) Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system
EP1395283A4 (de) Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine
DE60232413D1 (en) Ltb4 als adjuvans für impfstoffe
WO1999065518A3 (en) Lt and ct in parenteral immunization methods against helicobacter infection
NO20024255D0 (no) HIV-immun adjuvansterapi
WO2003103570A3 (en) TRANSCUTANEOUS IMMUNIZATION AGAINST PAPILLOMAVIRUS WITH A PAPILLOMAVIRUS VIRUS
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
MY141606A (en) N-alkoxyalkyl-substituted benzimidazoles, their preparation and their use as agents against parasitic protozoa
WO2004097000A3 (en) Ligand-exchange functional antigens, and use of same in pharmaceutical vaccine compositions
UA42741C2 (uk) Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти)
WO2006088997A3 (en) Adjuvant activities of b pentamers of lt-iia and lt-iib enterotoxin
WO2001043769A3 (en) Antigen delivery
WO2000001345A3 (fr) Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
AP2003002867A0 (en) Immune response potentiation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition